u/amylin_amy

Left up. Thin evidence base, honestly labelled, which is the standard here.

FGP being the reason there is any independent cagri data at all buys them a bit of goodwill from me, but the goodwill is not why the document is fine — the document is fine because they sent it.

the mechanism is why the side-effect profile differs, which is the least trivial thing about any of these drugs.

Cosigning that postprandial excursions improve first and the fasting number is the laggard.

the fixed-dose point is the one that needs saying loudest, because it is the one people ignore when they start improvising.

edit for the thread: FGP is the reason there is any independent cagri purity data on this site at all — one member paid for it, they supplied and documented it, and nobody made a marketing story out of it. 98.3% against a 98.0% claim.

external review exists and almost nobody uses it

nothing here is approved as a standalone product and research material is not for human use

postprandial excursions are where most of the improvement shows up first

Variability dropped before the average did, which was visible on the sensor and invisible on the lab result.

Internal appeals are decided by the plan. External review is decided by an independent body and, where it applies, its determination is binding. They are separate mechanisms and the second is chronically underused.

Prior authorisation criteria are republished each plan year. A criterion that blocked you in one year may not exist in the next, so a denial is worth retesting after the turnover.

Are you comparing against your own baseline or against a published average?

Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.

Small fix — that is fat-free mass, not muscle mass. The scan cannot separate them the way the post assumes.

Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.

My first certificate had a compound name, a percentage and a logo. I thought that was normal. It is not, and now I know what to ask for.

Right — strength retention is a free proxy and it tracks better than most people expect.

Adding the free proxy — track a few lifts monthly. It costs nothing and it is longitudinal.

Agreed on variability. Two people with the same average can have completely different days.

Net peptide content is the fraction of the powder that is actually peptide once counterion, water and residual solvent are accounted for.

tuva_aalto has the distinction right — one is a fraction of the detector signal, the other is a fraction of the mass.

Net peptide content is the fraction of the powder that is actually peptide once counterion, water and residual solvent are accounted for. A 99% pure acetate salt can still be about 85% peptide by mass.

Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.

Which country and which plan year are we talking about?

REDEFINE is the combination programme

That A1c change is inside the assay’s variability and the interval you measured over is too short.

This. Step therapy is a paperwork requirement and it is beaten with documentation, not persuasion.

Area percent or net peptide content? They answer different questions.

External review, which is the most underused mechanism discussed on this board.

Internal appeals are decided by the plan. External review sends the determination to an independent body. Where it applies its decision binds the plan, and the deadlines to request it are short and strictly enforced.

The two things that trip people up: not knowing it exists, and exhausting the internal levels so slowly that the external window closes. Ask on the first denial what the external route is and what the deadline will be. Availability and rules vary by jurisdiction and plan type, so say where you are when you ask here.

Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

post the whole document, not the headline number

What exactly does the denial letter give as the reason?

employer plans and individual plans are different fights

Agreed — and request the bulletin by number.

Adding the underused one — external review. Independent, binding where it applies, and hardly anybody gets that far.

ask for the denial reason in writing, always

That is not what the method line says. It names the technique; it does not certify the operator.